May 27th 2024
A phase 2b dose-finding study suggests use of clazakizumab was associated with a reduction in hs-CRP among patients undergoing maintenance dialysis.
Managing CKD in the Face of a Growing Diabetes Epidemic, with Amy Mottl, MD
October 17th 2022In an interview at the 6th annual Cardio-Endo-Renal Collaborative from Physicians' Education Resource, Amy Mottl, MD, provides perspective on recent data from the CURE-CKD registry and problems facing nephrologists as they cope with an increasing prevalence of diabetes.
Study Details "Troubling" Rates of Chronic Kidney Disease in People with Diabetes
October 14th 2022An analysis of data from more than 640,000 people with diabetes recorded between 2015-2020 is providing new insight into what study investigators are calling "troubling" trends in the incidence of CKD in the face a growing diabetes epidemic.
Risk of Kidney Decline in T1D Heightened for People of African Caribbean Ethnicity
September 3rd 2022An analysis of data from more than 5500 people with type 1 diabetes and preserved kidney function at baseline suggests patients of African Caribbean ethnicity had a more than 50% greater risk of kidney function decline of 50% or greater than patients of other ethnic backgrounds.
Finerenone Reduces All-Cause Mortality, Sudden Cardiac Death in Type 2 Diabetes
August 29th 2022An analysis of the FIDELITY program from ESC Congress 2022 details an 11% reduction in risk of all-cause mortality and a 25% reduction in risk of sudden cardiac death among patients with type 2 diabetes and chronic kidney disease.
Real-World Data Links Rosuvastatin to Nephrotoxicity
July 22nd 2022An analysis of real-world EHR data from more than 900,000 statin users suggests use of rosuvastatin was associated with an 8% greater risk of hematuria, a 17% greater risk of proteinuria, and a 15% higher risk of developing kidney failure requiring replacement therapy such as dialysis or transplantation compared to atorvastatin use.
Increased Physical Activity Linked to Lower Cardiovascular Risk in Chronic Kidney Disease
July 13th 2022An analysis of patients with CKD from the CRIC study demonstrates those with the highest levels of physical activity had reductions in risk of 36%, 29%, and 53% for atherosclerotic events, incident heart failure, and cardiovascular mortality, respectively, compared to those with the lowest levels.
Invasive Approach More Beneficial than Medical Management for NSTEMI in Chronic Kidney Disease
June 24th 2022New research from Indiana University details the impact of an invasive management strategy compared to medical management among patients with NSTEMI and chronic kidney disease across the spectrum of CKD severity.
Time to Rethink Metformin as First-Line Therapy? Perspective from ADA 2022
June 6th 2022After new data from the Diabetes Prevention Program Outcomes Study suggested neither metformin nor lifestyle intervention addressed the cardiovascular risk in patients with prediabetes, we asked experts at ADA 2022 if it was time to rethink metformin as first-line therapy in type 2 diabetes.
Tirzepatide and Kidney Outcomes, with Hiddo Heerspink, PharmD, PhD
June 5th 2022Hiddo Heerspink, PharmD, PhD, discusses a SURPASS-4 analysis examining kidney outcomes among patients receiving tirzepatide vs insulin glargine and provides perspective on the next steps for research as well as education.
Tirzepatide Use Can Slow Progression of CKD in Type 2 Diabetes
June 3rd 2022An analysis of SURPASS-4 data presented at ADA 2022 details the apparent reduction in progression of chronic kidney disease observed with use of tirzepatide compared to insulin glargine in the phase 3 trial, with a 41% reduction in progression of CKD in T2D.
No Increased Risk of Fracture with SGLT2 Inhibitors in Diabetic Kidney Disease, Study Finds
May 27th 2022Analysis of data from more than 75k patients with diabetes in Canada suggests use of SGLT2 inhibitors was not associated with an increased fracture risk compared with DPP-4 inhibitors among patients with diabetic kidney disease.
Initial eGFR Dips Common with SGLT2 Inhibitors, Not Typically Associated with Negative Outcomes
April 25th 2022An analysis of the DAPA-HF trial provides insight into the occurrence of eGFR dips in the first 14 days following initiation of therapy with an SGLT2 inhibitor and their association with long-term outcomes.
Finerenone Provides Consistent Benefit for Reducing CV Risk, Regardless of CVD History
April 9th 2022A prespecified analysis of FIDELITY presented at ACC.22 details the effects of finerenone on reducing cardiovascular risk based on whether or not patients had a history of atherosclerotic cardiovascular disease at baseline.
Finerenone Reduces CV Risk in T2D and CKD, Regardless of ASCVD History
April 7th 2022A prespecified analysis of FIDELITY details the effects of finerenone against placebo therapy for reducing the risk of cardiovascular events based on history of ASCVD among patients with type 2 diabetes and chronic kidney disease.
Sotagliflozin Reduces Stroke, MI, and CV Death, Regardless of CVD History
April 4th 2022Deepak Bhatt, MD, MPH, breaks down data from the SCORED trial presented at ACC.22, which demonstrated sotagliflozin provided significant benefit in terms of reducing total MACE, total MI, and total stroke, regardless of whether a patient had a history of cardiovascular disease.
Deepak Bhatt, MD, MPH: Estimating the Potential US Patient Population for Finerenone
April 4th 2022We sat down with Deepak Bhatt, MD, MPH, at ACC.22 to discuss a study he took part in assessing the potential patient population of finerenone using eligibility criteria from FIDELIO-DKD and FIGARO-DKD against information from NHANES.
GLP-1 RAs Could Lower Mortality Risk in Type 2 Diabetes with Advanced CKD
March 8th 2022A retrospective cohort study suggests use of GLP-1 RAs was associated with a 21% reduction in risk of all-cause mortality in patients with type 2 diabetes and advanced-stage chronic kidney disease compared with DPP-4 inhibitors.